New collaboration with RefLab shows beneficial properties of lead candidate epidermicin NI01 for topical skin therapy
by Mathew Upton
January 2022
Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models.
Amprologix and RefLab ApS (Copenhagen, Denmark) have collaborated on a project using an ex vivo human skin microdialysis model (below) to test pseudo-allergic reactions in the skin, without using animal models. Data clearly demonstrated that lead candidate epidermicin NI01 does not have any pseudo-allergic liabilities, consistent with its wider performance in pre-clinical toxicology tests. This is in stark contrast to some peptide-based antimicrobials, which have failed pre-clinical workup due to stimulation of allergic responses.
Working with ex-vivo human skin gives good confidence that future applications to humans will be a safe and efficacious way to treat skin infections caused by leading pathogens like MRSA.
